APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside

Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple.

Analyst Commentary

Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.

Bullish Takeaways

Bullish analysts point to 2026 guidance that sits above prior Street expectations and view this as a sign of confidence in the company’s medium term growth path and earnings power.
The upcoming liposuction handpiece approval, which is not included in current 2026 guidance, is seen as a potential source of incremental revenue and upside to current valuation frameworks.
Early momentum with the Ayon launch and rising demand for skin tightening among consumers using GLP-1s are viewed as supportive drivers for procedure volumes and system utilization.
International expansion via new country approvals and broader access to GLP-1 treatments is seen as a way to widen the addressable market beyond the U.S. and support longer term revenue growth assumptions.

Bearish Takeaways

Some cautious analysts flag that 2026 guidance, while above previous Street expectations, still excludes potential contribution from the liposuction handpiece. This introduces uncertainty around how quickly that opportunity can be realized.
Execution on international expansion and new country approvals is viewed as a key swing factor. Any delays or slower uptake could affect growth trajectories that bullish analysts are using in their models.
Although cost controls are improving visibility into a path toward sustainable profitability, skeptics may question how consistently these controls can be maintained as the company invests in product launches and global expansion.
Rising expectations embedded in higher price targets could leave less room for missteps. Any shortfall relative to guidance or slower adoption of Ayon and GLP-1 related procedures could pressure valuation assumptions.

What’s in the News

Publication of a retrospective 113 patient study in Plastic and Reconstructive Surgery Global Open, where adding Renuvion to power assisted liposuction was associated with higher patient reported satisfaction on Body Q scores, lower rates of abdominoplasty and fewer revisions, with similar complication rates compared with power assisted liposuction alone (Key Developments).
Study findings link Renuvion based procedures to higher satisfaction with reduced excess abdominal skin and abdominal appearance, including more than 50% lower abdominoplasty rates and lower revision rates in the Renuvion cohort, which may factor into how surgeons think about treatment planning and capital equipment needs (Key Developments).
Apyx Medical highlights the AYON Body Contouring System as building on the clinical experience of Renuvion, combining fat removal, tissue contraction and electrosurgical capabilities in one platform for body contouring procedures (Key Developments).
The company received expanded 510(k) clearance from the U.S. Food and Drug Administration for AYON to include power liposuction, integrating this modality into the same system to support workflow and operating room efficiency goals (Key Developments).
Apyx Medical revised its financial guidance for the year ending December 31, 2026, with total revenue now expected in a range of $59.0 million to $60.0 million compared with prior guidance of $57.5 million to $58.5 million and reported revenue of $52.8 million for 2025 (Key Developments).

Valuation Changes

Fair Value: The target has risen slightly to $6.50 from $6.40.
Discount Rate: The assumption has fallen slightly to 7.99% from 8.42%, reflecting an updated risk view in the model.
Revenue Growth: The forecast has risen slightly to 13.67% from 12.81%, indicating a modestly higher top line expectation.
Net Profit Margin: The assumption has edged down to 12.19% from 12.79%, pointing to slightly lower expected profitability.
Future P/E: The valuation multiple has been trimmed to 41.7x from 42.9x, implying a modestly lower earnings multiple applied to future results.

0 views

Key Takeaways

Strong adoption of AYON system and expansion into China are expected to accelerate revenue growth and increase international market presence.
Strategic hires and cost reduction initiatives enhance sales execution, operational efficiency, and support margin expansion and long-term earnings improvement.
Revenue instability, ongoing losses, market challenges, international risk, and dependence on a few products threaten Apyx Medical's growth, profitability, and long-term stability.

Catalysts

About Apyx Medical

An energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The recent launch and enthusiastic early adoption of the AYON system-a next-generation, comprehensive body contouring platform-defies broader industry softness, as surgeons seek innovative, workflow-improving minimally invasive solutions. This is likely to accelerate revenue growth and expand operating leverage as commercial adoption ramps in the second half of 2025 and beyond.
The company's expansion into China, supported by a well-connected distribution partner and newly granted market clearance, positions Apyx to capture demand from a large and rapidly growing middle
and upper-class population seeking aesthetic procedures, boosting international revenue growth over the next several years.
Strategic senior sales hires for North America, Europe, and Asia, each with deep experience in driving adoption of advanced aesthetic devices, are expected to strengthen local sales execution and market penetration, increasing recurring revenue streams and supporting potential improvements in operating margins.
Apyx is poised to benefit from the growing market of patients experiencing skin laxity post-significant weight loss, particularly those on GLP-1 drugs-a demographic that is expanding rapidly and fueling demand for minimally invasive procedures, supporting higher volumes and top-line growth.
Recent cost-reduction and restructuring initiatives have meaningfully improved the company's cash burn and operating expense base, enhancing financial flexibility to invest in product innovation and commercial growth, which should support margin expansion and future earnings improvement.

Apyx Medical Earnings and Revenue Growth

Apyx Medical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Apyx Medical's revenue will grow by 13.7% annually over the next 3 years.
Analysts are not forecasting that Apyx Medical will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Apyx Medical's profit margin will increase from -16.4% to the average US Medical Equipment industry of 12.2% in 3 years.
If Apyx Medical's profit margin were to converge on the industry average, you could expect earnings to reach $10.0 million (and earnings per share of $0.2) by about May 2029, up from -$9.2 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 42.0x on those 2029 earnings, up from -18.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.0%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company's overall revenue declined year-over-year, primarily from a 29% drop in the OEM segment, and domestic Advanced Energy sales saw stagnant or modest decreases, indicating potential difficulty in maintaining consistent top-line growth-this instability may pressure future revenue and earnings.
Ongoing net losses, with a $3.8 million net loss in Q2 2025 and cash burn albeit reduced, suggest that Apyx has yet to achieve sustainable profitability, and continued high operating expenses, if not offset by strong sales growth, could further delay positive net margins and earnings.
The aesthetic medical device market remains "challenged" with subdued capital equipment spending, and despite early excitement around AYON, there is execution risk if enthusiasm does not translate to sustained adoption as broader customer segments may remain hesitant-potentially resulting in lower-than-anticipated revenue growth and margin pressure.
International expansion, particularly in China, is in a nascent phase; initial sales and partnerships look promising but expose Apyx to heightened geopolitical, regulatory, and market entry risks, which could impact both revenue reliability and international profitability.
The company remains highly reliant on Renuvion and AYON products, with limited mention of further diversification; setbacks such as intensified competition, disappointing clinical outcomes or shifting customer preferences toward non-invasive alternatives may significantly impact Apyx's market share, thereby increasing revenue volatility and risk to long-term margin and earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $6.5 for Apyx Medical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $6.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $82.1 million, earnings will come to $10.0 million, and it would be trading on a PE ratio of 42.0x, assuming you use a discount rate of 8.0%.
Given the current share price of $4.0, the analyst price target of $6.5 is 38.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Apyx Medical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Minimally Invasive Aesthetic Procedures Will Expand International Markets